Stabilization of physical RAF/14-3-3 interaction by cotylenin A as treatment strategy for RAS mutant cancers

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Somatic RAS mutations are prevalent in human cancers, driving aberrant RAF kinase signaling.
• Current RAF inhibitors show efficacy in some cancers but paradoxically promote RAS-mutant tumor growth.
• RAF homo- and heterodimerization complexity contributes to treatment resistance.

Purpose of the Study:

• To identify novel therapeutic strategies for RAS-mutant cancers.
• To investigate the mechanism of action of the natural product cotylenin-A (CN-A).
• To evaluate the synergistic effect of CN-A combined with anti-EGFR therapy.

Main Methods:

• Pathway analysis and structure-guided compound identification.
• Characterization of CN-A's interaction with C-RAF and 14-3-3 proteins.
• In vitro and in vivo evaluation of CN-A and anti-EGFR antibody combination therapy in RAS-mutant cancer models.

Main Results:

• Cotylenin-A (CN-A) was identified as a stabilizer of C-RAF and 14-3-3 protein interactions.
• CN-A binds to inhibitory sites (pSer233, pSer259) on C-RAF, not the activating site (pSer621).
• Combined treatment of CN-A and an anti-EGFR antibody demonstrated synergistic tumor growth suppression in RAS-mutant cancer models.

Conclusions:

• CN-A represents a novel pharmacologic agent targeting C-RAF-14-3-3 interactions.
• The combination of CN-A and anti-EGFR antibodies offers a promising therapeutic strategy for RAS-mutant cancers.
• This approach addresses the limitations of current RAF inhibitors in RAS-driven malignancies.